MURRELLS INLET, SC (WMBF) - A Murrells Inlet family is back from a trip to Capitol Hill advocating to continue research funding for a rare disease called Tuberous Sclerosis Complex ... when doctors ...

Marinus Pharmaceuticals has reported that the Phase III TrustTSC trial of oral ganaxolone in treating seizures linked to ...

TSC is a rare genetic condition that mainly causes non-cancerous (benign) tumors to develop in different body parts. Also Read: Marinus Pharmaceuticals Shares Mixed Results From IV Formulated ...

In Marnius’ TrustTSC study, Ztalmy (ganaxolone) didn’t meet its primary endpoint of percent change in tuberous sclerosis complex (TSC)-associated seizure frequency, the company reported.

The event will raise funds to further tuberous sclerosis complex (TSC) research and expand support programs for individuals and families affected by the disease. Formed in 1974 by four mothers ...

stock plunged after the company revealed disappointing data from the Phase 3 TrustTSC trial of oral ganaxolone for seizures associated with tuberous sclerosis complex (TSC) in children and adults.